Abstract
Background: Adenocarinomas frequently adopt mesenchymal properties to become metastatic, aggressive and drug-resistant. Non-small cell lung cancer (NSCLC), a leading cause of cancer-related deaths, is a well-understood cancer type to utilize an epithelial-to-mesenchymal transition (EMT) to acquire drug resistance in preclinical models. This is particularly applicable in resistance to EGFR inhibitors (e.g. osimertinib) in EGFR+ NSCLC, where resistance has been linked to EMT and increased AXL expression, a known driver of the mesenchymal phenotype.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
